Protalix BioTherapeutics
PLX
PLX
38 hedge funds and large institutions have $39.4M invested in Protalix BioTherapeutics in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
7.68% more ownership
Funds ownership: 12.26% → 19.94% (+7.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $1.23M
Holders
38
Holding in Top 10
1
Calls
$1.08M
Puts
$1.23M
Top Buyers
| 1 | +$11.7M | |
| 2 | +$5.37M | |
| 3 | +$1.32M | |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$1.09M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$661K |
Top Sellers
| 1 | -$1.54M | |
| 2 | -$183K | |
| 3 | -$85K | |
| 4 |
Squarepoint
New York
|
-$80K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$36K |